Trend of Anticoagulant Therapy in Elderly Patients with Atrial Fibrillation Considering Risks of Cerebral Infarction and Bleeding

Overview

Journal Sci Rep

Specialty Science

Date 2023 Jan 5

PMID 36604482

Authors

Noriko Tsuji

Yoshimitsu Takahashi

Michi Sakai

Shosuke Ohtera

Junji Kaneyama

Kosai Cho

Genta Kato

Shigeru Ohtsuru

Takeo Nakayama

Affiliations

Soon will be listed here.

Abstract

The introduction of direct oral anticoagulants (DOACs) has greatly changed the use of anticoagulant therapy in patients with non-valvular atrial fibrillation (Af). Therefore, this study aimed to examine changes in the proportions of oral anticoagulant prescriptions in patients with non-valvular Af aged ≥ 65 years, taking into consideration the risk of cerebral infarction and bleeding. Anticoagulant prescriptions in outpatients aged ≥ 65 years with Af were temporally analyzed using the nationwide claims database in Japan. Trends in anticoagulant prescriptions were examined according to cerebral infarction and bleeding risk. The proportion of anticoagulant prescriptions for 12,076 Af patients increased from 41% in 2011 to 56% in 2015. An increase in DOAC prescriptions was accompanied by an increase in the proportion of anticoagulant prescriptions in each group according to the CHA2DS2-VASc and HAS-BLED scores. The proportion of anticoagulant prescriptions for patients with a high risk of developing cerebral infarction and bleeding showed a marked increase. Trends in anticoagulant prescriptions in Af patient with a CHADS-VASc score ≥ 2 and HAS-BLED scores ≥ 3 showed a marked increase in DOAC prescriptions. The widespread use of DOACs greatly changes the profile the prescription of anticoagulant therapy in patients with Af.

Citing Articles

National trends in hospitalizations for gastrointestinal bleeding in Japan.

Ichita C, Goto T, Sasaki A, Shimizu S J Clin Biochem Nutr. 2024; 75(1):60-64.

PMID: 39070532 PMC: 11273266. DOI: 10.3164/jcbn.23-111.

References

Ohshima A, Koyama T, Ogawa A, Zamami Y, Tanaka H, Kitamura Y . Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data. Fam Pract. 2019; 36(6):685-692. DOI: 10.1093/fampra/cmz016. View

Lin H, Wolf P, Beiser A, Kase C, Benjamin E, DAgostino R . Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996; 27(10):1760-4. DOI: 10.1161/01.str.27.10.1760. View

Behdarvand B, Karanges E, Bero L . Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study. BMJ Open. 2019; 9(8):e030253. PMC: 6707659. DOI: 10.1136/bmjopen-2019-030253. View

Chang S, Chou I, Yeh Y, Chiou M, Wen M, Kuo C . Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA. 2017; 318(13):1250-1259. PMC: 5818856. DOI: 10.1001/jama.2017.13883. View

Kumazawa R, Jo T, Matsui H, Fushimi K, Yasunaga H . Direct oral anticoagulants versus warfarin for secondary prevention of cerebral infarction and bleeding in older adults with atrial fibrillation. J Am Geriatr Soc. 2022; 70(7):2029-2039. DOI: 10.1111/jgs.17770. View

Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M . Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019; 381(12):1103-1113. DOI: 10.1056/NEJMoa1904143. View

Yokoyama S, Tanaka Y, Nakagita K, Hosomi K, Takada M . Bleeding Risk of Warfarin and Direct Oral Anticoagulants in Younger Population: A Historical Cohort Study Using a Japanese Claims Database. Int J Med Sci. 2018; 15(14):1686-1693. PMC: 6299405. DOI: 10.7150/ijms.28877. View

Maura G, Billionnet C, Drouin J, Weill A, Neumann A, Pariente A . Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. BMJ Open. 2019; 9(4):e026645. PMC: 6500377. DOI: 10.1136/bmjopen-2018-026645. View

Forslund T, Komen J, Andersen M, Wettermark B, von Euler M, Mantel-Teeuwisse A . Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants. Stroke. 2018; 49(9):2122-2128. DOI: 10.1161/STROKEAHA.118.021990. View

10.

Inoue H, Atarashi H, Kodani E, Okumura K, Yamashita T, Origasa H . Regional Differences in Frequency of Warfarin Therapy and Thromboembolism in Japanese Patients With Non-Valvular Atrial Fibrillation　- Analysis of the J-RHYTHM Registry. Circ J. 2016; 80(7):1548-55. DOI: 10.1253/circj.CJ-16-0300. View

11.

Verma A, Cairns J, Mitchell L, Macle L, Stiell I, Gladstone D . 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014; 30(10):1114-30. DOI: 10.1016/j.cjca.2014.08.001. View

12.

Olesen J, Sorensen R, Hansen M, Lamberts M, Weeke P, Mikkelsen A . Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace. 2014; 17(2):187-93. DOI: 10.1093/europace/euu225. View

13.

. Guidelines for elective percutaneous coronary intervention in patients with stable coronary artery disease (JCS 2011) published in 2012--digest version. Circ J. 2013; 77(6):1590-607. DOI: 10.1253/circj.cj-66-0065. View

14.

Kubota K, Ooba N, Kamijima Y, Sato K, Koide D . The use of anticoagulants in patients with non-valvular atrial fibrillation between 2005 and 2014: A drug utilization study using claims data in Japan. PLoS One. 2018; 13(9):e0203380. PMC: 6124773. DOI: 10.1371/journal.pone.0203380. View

15.

January C, Samuel Wann L, Calkins H, Chen L, Cigarroa J, Cleveland Jr J . 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the.... J Am Coll Cardiol. 2019; 74(1):104-132. DOI: 10.1016/j.jacc.2019.01.011. View

16.

Pisters R, Lane D, Nieuwlaat R, de Vos C, Crijns H, Lip G . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5):1093-100. DOI: 10.1378/chest.10-0134. View

17.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38):2893-2962. DOI: 10.1093/eurheartj/ehw210. View

18.

Avezum A, Lopes R, Schulte P, Lanas F, Gersh B, Hanna M . Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015; 132(8):624-32. DOI: 10.1161/CIRCULATIONAHA.114.014807. View

19.

Okamoto E . Linkage rate between data from health checks and health insurance claims in the Japan National Database. J Epidemiol. 2013; 24(1):77-83. PMC: 3872528. DOI: 10.2188/jea.je20130075. View

20.

Narita N, Okumura K, Kinjo T, Mikami J, Tsushima K, Takahashi R . Trends in Prevalence of Non-Valvular Atrial Fibrillation and Anticoagulation Therapy in a Japanese Region　- Analysis Using the National Health Insurance Database. Circ J. 2020; 84(5):706-713. DOI: 10.1253/circj.CJ-18-0989. View